The Canberra Hospital
Welcome,         Profile    Billing    Logout  
 22 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rao, Krishna
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
MARC, NCT02324582: MK-3475/BCG in High Risk Superficial Bladder Cancer

Completed
1
18
US
Intravenous MK-3475/ Intravesical BCG, pembrolizumab
Southern Illinois University, Merck Sharp & Dohme LLC
Bladder Cancer
11/21
03/23
Brown, Karen T
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
Fields, Ryan
NCT04536077: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
2
16
US
CDX-301, CDX-1140, Research blood draw
Washington University School of Medicine, Celldex Therapeutics, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
11/23
11/23
NCT04412629: Cabozantinib in High Grade Neuroendocrine Neoplasms

Recruiting
2
32
US
Cabozantinib, Cabometyx, Blood for plasma biomarkers, Tissue biopsy
Washington University School of Medicine, Exelixis
High Grade Neuroendocrine Neoplasms
07/25
03/26
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
Heerspink, Hiddo J Lambers
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Recruiting
4
17
Canada
Dapagliflozin 10 MG [Farxiga]
George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
03/22
04/22
Optimize@Home, NCT06094920: Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Enrolling by invitation
4
10
Europe
Empagliflozin 10 MG, Jardiance, A10BK03, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, Finerenone, Kerendia, C03DA05, (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, Withings BPM Connect, Withings Body, PeeSpot Urine Collection Device, Hem-Col Capillary Blood Collection Device, Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
University Medical Center Groningen, Boehringer Ingelheim
Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
10/24
11/24
ZODIAC, NCT05570305 / 2021-001324-18: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Enrolling by invitation
2
38
Europe, Canada, US
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
University Medical Center Groningen, AstraZeneca
Chronic Kidney Diseases
04/24
09/24
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
NCT04389827: Global Kidney Patient Trials Network

Recruiting
N/A
6000
RoW
The George Institute, George Clinical Pty Ltd
Kidney Diseases
04/25
04/30
Pathak, Rajeev
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
NCT04863664: Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)

Recruiting
N/A
975
Europe, Canada, Japan, US, RoW
Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
Medtronic Cardiac Rhythm and Heart Failure
Tachyarrhythmia
06/25
02/26
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
03/26
03/26
Talaulikar, Girish S
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Calendar Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease
Recruiting
3
2000
Europe, Canada, RoW
Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo
The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
06/27
12/27
Palfreyman, Emma
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
Crassini, Kyle
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
Investigator, Phillip Braslins Principal
No trials found

Download Options